Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that PD-L1 (CPS) >= 10 status confers therapeutic sensitivity to Cisplatin, Fluorouracil, Pembrolizumab in patients with Esophageal Adenocarcinoma.
The Republic of Ireland's Health Service Executive (HSE) has approved pembrolizumab (200mg) in combination with platinum and flouropyrimidine-based chemotherapy for reimbursement as a treatment option for the first-line treatment of adult patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma whose tumors express PD-L1 with CPS >= 10.
This statement is based on a regulatory approval from the Health Service Executive:
Pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy, for the first line treatment of patients with locally advanced unresectable or metastatic carcinoma of the oesophagus or HER-2 negative gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with CPS >= 10.